ATTENTION: Please enable Javascript in your browser for full site functionality.
Skip to navigation Skip to main content Skip to footer

Updates

SUB-TYPE:

Hinckley service update 30 November 

 

We have experienced an exceptional increase in order volume at our Hinckley Service Centre which has impacted our ability to process some orders. Despite robust planning to ensure service consistency throughout the peak season (where an uplift in volume is always anticipated), our Hinckley site experienced an unprecedented increase overnight. 

 

You may be missing some items in your deliveries this afternoon. For assurance, all fridge and controlled drug items are unaffected and will arrive with you as normal. Any items you do not receive this afternoon will be with you tomorrow morning – you do not need to re-order.

 

Please contact Customer Service for any emergency requirements.

 

In order to support our recovery, we need to make a temporary change to this evening's order cut off time to 5pm. Please try to transmit orders before this time. We are sorry for any inconvenience this causes you or your patients and thank you in advance for your understanding. 

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Medicines Defect Information: Lucis Pharma Ltd, Oxycodone Hydrochloride 10mg/ml oral solution

Lucis Pharma Ltd has informed the MHRA that there is a typographical error with text on the rear side of the outer packaging for Oxycodone Hydrochloride 10mg/ml Oral Solution.

 

MHRA drug alert date: 29 November 2022

 

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-lucis-pharma-ltd-oxycodone-hydrochloride-10mg-slash-ml-oral-solution-el-22-a-slash-49?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=1864253f-7b0a-4b30-9aad-78ec2edb6c19&utm_content=immediately

Pip code

Product description

Supplier

Batch Numbers

ALLIANCE DO NOT SOCK

OXYCODONE HYROCHLORIDE 10MG/ML ORAL SOLUTION

LUCIS PHARMA LTD

21050004 

22080005

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.

 

Further information

For medical information and stock control queries please contact: enquiries@lucispharma.co.uk.

 

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

SUB-TYPE:

Christmas and New Year Bank Holiday Opening Hours 2022

 

To help keep our customers informed of changes to our service, we have published our bank holiday opening hours for the 2022 Christmas and New Year period.

 

View our bank holiday opening hours:

For Pharmacy/Retail – Christmas and New Year Bank Holiday Opening Hours 2022

For Hospitals – Christmas and New Year Bank Holiday Opening Hours 2022

SUB-TYPE:

CLASS 4 CAUTION IN USE - HYOSCINE BUTYLBROMIDE 20 MG FILM-COATED TABLETS

Morningside Healthcare Limited has informed the MHRA of an error with the Patient Information Leaflet (PIL) packaged in batch 22237001 of Hyoscine Butylbromide 20 mg Film-coated Tablets. Some packs within the batch may contain a PIL for Midodrine Hydrochloride 2.5 mg & 5 mg Tablets. The issue was identified due to a market complaint, which noted that a Midodrine Hydrochloride 2.5 mg & 5 mg Tablets leaflet had been found in a pack of Hyoscine Butylbromide 20 mg Film-coated Tablets, batch 22237001, expiry date 04/2025.

MHRA drug alert date: 21st November 2022

Alliance Healthcare Pip code

C+D Pip code

Product Description

Supplier

Batch Numbers

8043788

1256890

HYOSCINE BUTYLBROMIDE 20 MG FILM-COATED TABLETS

MORNINGSIDE HEALTHCARE LTD

22237001

 

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-morningside-healthcare-limited-hyoscine-butylbromide-20-mg-film-coated-tablets-el-22-a-slash-48?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=cfd26f4f-9046-4674-9924-980b00650278&utm_content=immediately

 

This is a caution in use only we are not accepting stock returns.

 

Further Information:

For further information please contact: Morningside Healthcare Ltd, Morningside House, Unit C Harcourt Way, Meridian Business Park, Leicester, LE19 1WP,

Telephone: +44 (0)116 2045950

 

For medical information enquiries, please contact: medicalenquiry@morningsidehealthcare.com or Telephone +44 (0)116 478 0322 and for all stock enquiries, please contact Telephone: +44 (0)1162045950

SUB-TYPE:

Alliance Healthcare and Alphega Pharmacy are proud support World Antimicrobial Awareness Week

 

Alliance Healthcare and Alphega Pharmacy are proud to be supporting World Antimicrobial Awareness Week which runs from the 18 to the 25 November. The week aims to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices for using antimicrobials, in order to avoid further emergence of and the spread of drug-resistant infections.

 

Marie Evans, Managing Director, Alliance Healthcare said: “I am proud that we are supporting AMR week to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices for using antimicrobials. It is important to share awareness of this and pledge our support along with the NHS.”

 

Keep Antibiotics Working’ is the UK-wide campaign, which supports the government’s continued efforts to reduce inappropriate prescriptions for antibiotics. The campaign warns people that taking antibiotics when they are not needed puts them at risk of a more severe or longer infection and urges people to take their doctor’s advice on antibiotics.

 

To help pharmacy teams spread awareness of the campaign within their pharmacies, we have created a website to share the NHS digital resources available via the NHS, which include:

 

  1. > Posters
  2. > Digital Screens
  3. > Leaflets

AMRC

 

We are encouraging our customers to get on board and support the campaign. In addition, the Alphega Pharmacy team are offering additional guidance on the Pharmacy Quality Scheme (details below), and Business Mentor level support.

 

PQS E-learning requirement

As part of the PQS E-learning, pharmacy contractors in England who chose to access the PQS renumeration criteria via the PSNC website can complete their *PQS Antimicrobial Stewardship (AMS) to assess their practice and complete e-learning assessments which must be completed by the end of March 2023.

 

Alphega Members

As part of their membership fee, Alphega members are being offered support to complete the *PQS AMS for AMR (antimicrobial stewardship) as well as a comprehensive PQS toolkit for all their PQS requirements.


Support us and the NHS during World Antimicrobial Awareness Week

Alliance Healthcare has pledged to become an Antibiotic Guardian and are proud to support this campaign. Find out more here.

​​​​​

 

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Medicines Defect Information: Martindale Pharma Venlafaxine 300mg XL Prolonged release tablets

 

Martindale Pharma has made the MHRA aware that the GTIN in the 2D barcode and the printed variable data represents the branded version of the product (Venlalic® XL 300 mg prolonged-release tablets).

 

MHRA drug alert date:  16 November 2022

 

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-macarthys-laboratories-t-slash-a-martindale-pharma-venlafaxine-xl-300-mg-prolonged-release-tablets-el-22-a-slash-47?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=499d8039-6eda-43fe-8884-9605b56b0d82&utm_content=immediately

 

 

Pip code

Product description

Supplier

Batch Numbers

8047318

1257559

8045320

VENLAFAXINE XL TAB 300MG

MARTINDALE PHARMA

LC69391

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.

 

Further Information

For further information, medical enquiries and stock information, contact: Licensed@ethypharm.com

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Medicines Defect Information: PRENOXAD 1MG/ML INJECTION

Macarthys Laboratories (trading as Martindale Pharma, an Ethypharm Group Company), has notified the MHRA of a limited number of Prenoxad packs in a batch marketed in France with missing needles.

MHRA drug alert date: 10th November 2022

 

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/national-patient-safety-alert-class-4-medicines-defect-information-prenoxad-1mg-slash-ml-solution-for-injection-macarthys-laboratories-aurum-pharmaceuticals-ltd-slash-ethypharm-group-due-to-potential-missing-needles-in-sealed-kits

 

Pip code

Product description

Supplier

Batch Numbers

  3797131

  PRENOXAD 1MG/ML INJECTION

ETHYPHARM GROUP COMPANY

116917

119973

120140

125553

125555

125724

126941

126943

130203

130732

130843

134251

136031

136536

136551

137656

137768

138525

138904

139907

140236

141035

141812

141969

 

 

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.

 

Further Information

For more information on licensed stock and resupply queries for the licensed presentation, please contact licensed@ethypharm.com; telephone number: 0800 028 7933.

 

For medical information queries and all other enquiries, please contact medinfo@ethypharm.com; telephone number 01277 266 600.

 

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

SUB-TYPE: COMPANY-LED RECALL

Company Led Recall-Activa Thigh Length Open Toe Hosiery class 2 XL size

L&R medical have informed us that on the affected batch of Activa Thigh Length Open Toe Hosiery XL the product inside the packaging is Small and not Extra Large

MHRA drug alert link: N/A   

PIP CODE

DESCRIPTION

SUPPLIER

AFFECTED BATCHES

2590883

ACTIVA T/L O/T C2 SND XL

L&R MEDICAL UK LTD

221909

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

 

For more information please contact L&R MEDICAL UK LTD

customerservices@uk.lrmed.com

Quality&Regulatory@uk.lrmed.com

 

 

 

SUB-TYPE: CLASS 3 RECALL

Class 3 Recall - Mebeverine hydrochloride 135mg Film-coated Tablets

Medreich Plc UK is recalling the above batch as a precautionary measure due to out of specification results for tablet dissolution during routine product release testing.

 

MHRA drug alert date: 27th October 2022

 

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-medreich-plc-mebeverine-hydrochloride-135mg-film-coated-tablets-el-22-a-slash-46?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=0b5b7f21-3a71-444e-be6b-ea061980a229&utm_content=immediately

 

Pip code

Product description

Supplier

Batch Numbers

1152123

MEBEVERINE TAB 135MG

MEDREICH PLC

B11539

1037514

MEBEVERINE TAB 135MG

MEDREICH PLC

B11539

8113110

OTCD MEBEVERINE TAB 135MG

MEDREICH PLC

B11539

 

Further Information

For more information or supply enquiries, please contact Medreich PLC at cs_team@medreich.co.uk or by phone at 0208 831 1580, 0208 831 1511 or 0208 831 1509

For medical information queries, please contact pharmacovigilance@medreich.com

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

 

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Medicines Defect Information: Recordati Rare Diseases, Pedea 5 mg/ml solution for injection

Recordati Rare Diseases T/A Recordati Rare Diseases UK Ltd has made the MHRA aware that specific batches of Pedea 5 mg/ml solution for injection have been packaged with the incorrect Product Information Leaflet (PIL).

 

MHRA drug alert date: 25th October 2022

 

MHRA drug alert link: 

https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-recordati-rare-diseases-pedea-5-mg-slash-ml-solution-for-injection-el-22-a-slash-45?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=8880eab9-9fb3-431a-85f0-7f29ba803bf5&utm_content=immediately

 

Pip code

Product description

Supplier

Batch Numbers

ALLIANCE DO NOT STOCK

PEDEA 5 MG/ML SOLUTION FOR INJECTION, 4 AMPOULES

RECORDATI RARE DISEASES T/A RECORDATI RARE DISEASES UK LTD

PD0G24E-07

PD0G24E-10

PF0G04E-03

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.

 

For further information, including medical enquiries and stock information, please contact:

Recordati Rare Diseases UK Ltd (local representative, WDA(H): 15720) on Tel: +44 (0)1491 414333 or +33 1 47 73 64 58 or email: RRDmedinfo@recordati.com

 

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to hospital pharmacists and pediatric doctors and nurses working in hospital setting for information.